Home
Approach
Product
About
News
Contact
News
Altis in the
news
.
Follow our journey to improving patient outcomes.
Filter
All
Announcements
Publications
Media Coverage
Altis Labs Announces Presentation of Results at ASCO 2025 Demonstrating IPRO-Δ Outperforms RECIST in Predicting Overall Survival in Phase 3 Trial
Altis Labs Announces Presentation of Results at ASCO 2025 Demonstrating IPRO-Δ Outperforms RECIST in Predicting Overall Survival in Phase 3 Trial
Altis Labs Partners with UHN on Multi-Year Collaboration to leverage AI in Cancer Imaging
Altis Labs Partners with UHN on Multi-Year Collaboration to leverage AI in Cancer Imaging
ISPOR: Real-World Digital Twins Replicate Control Arm Outcomes
ISPOR: Real-World Digital Twins Replicate Control Arm Outcomes
Altis Labs Unveils New AI-Powered External Control Arm Product Offering at ISPOR 2025
Altis Labs Unveils New AI-Powered External Control Arm Product Offering at ISPOR 2025
AACR: IPRO-Δ Predicts Overall Survival 8 Weeks Post 1L Systemic Treatment Initiation
AACR: IPRO-Δ Predicts Overall Survival 8 Weeks Post 1L Systemic Treatment Initiation
AACR: IPRO Significantly Outperforms SLD in Predicting OS in a Ph3 aNSCLC Trial
AACR: IPRO Significantly Outperforms SLD in Predicting OS in a Ph3 aNSCLC Trial
STAT News: This Canadian company’s AI tool could help drugmakers cut risk in late-stage cancer trials
STAT News: This Canadian company’s AI tool could help drugmakers cut risk in late-stage cancer trials
ELCC: IPRO Predicts Significant OS Differences at Week 8
ELCC: IPRO Predicts Significant OS Differences at Week 8
ELCC: IPRO Outperforms RECIST 1.1 in Predicting Overall Survival
ELCC: IPRO Outperforms RECIST 1.1 in Predicting Overall Survival
Altis Labs Announces Presentation of AI Model Evaluation on Data from Phase 3 Lung Cancer Trial at ELCC 2025
Altis Labs Announces Presentation of AI Model Evaluation on Data from Phase 3 Lung Cancer Trial at ELCC 2025
Previous
Next
Altis Labs leads $6 million pan-Canadian initiative to develop and commercialize imaging biomarkers using deep learning
Previous
IASLC WCLC: IPRO Response Rate detected treatment effects missed by ORR in MARIPOSA, a Phase 3 trial in EGFR-mutated aNSCLC
ASCO: Depth of IPRO-α response at week 8 is associated with progressively longer OS in advanced NSCLC patients treated with first-line pembrolizumab monotherapy
AACR: IPRO stratifies OS with greater prognostic discrimination than TNM substage in metastatic CRC.
ESMO: AI-Based Quantification of Longitudinal Body Composition Changes Shows Prognostic Associations in aNSCLC Patients in Real-World Data
ESMO: IPRO Response Rate Correlates More Strongly With OS Treatment Effects Than RECIST Objective Response Rate
CBCS: IPRO is generalizable to breast cancer, and provides higher discrimination of OS compared to TNM staging and age
ASCO: IPRO-Δ Predicts Overall Survival at Week 13, Outperforming RECIST in Phase 3 Trial
ISPOR: Real-World Digital Twins Replicate Control Arm Outcomes
AACR: IPRO-Δ Predicts Overall Survival 8 Weeks Post 1L Systemic Treatment Initiation
AACR: IPRO Significantly Outperforms SLD in Predicting OS in a Ph3 aNSCLC Trial
Next
STAT News: This Canadian company’s AI tool could help drugmakers cut risk in late-stage cancer trials
Inside Precision Medicine: How Is Artificial Intelligence Changing the Clinical Trials Landscape?
STAT News: As AI proliferates, biopharma companies seek to harness it in clinical trials
BiopharmaTrend: Ten AI Companies in Clinical Research to Watch in 2023
Fierce Biotech: AstraZeneca, Bayer gain early access to AI-driven 'digital twins' courtesy of Altis Labs collab
BetaKit: Altis Labs closes CAD $7.9 million to evaluate cancer treatments using AI
Axios: Clinical trial startup seeds $6M to speed research
Fierce Biotech: Altis Labs reels in $6M in seed funding for AI imaging used in clinical trials
.png)
.png)
.png)
.jpg)
.png)
.png)
.png)
.png)
.png)
.png)
